[VAD regimen for multiple myeloma--the effectiveness as first line therapy]

Area of Science:

• Hematology
• Oncology
• Clinical Pharmacology

Context:

• Multiple myeloma is a hematologic malignancy characterized by uncontrolled proliferation of plasma cells.
• Effective primary treatment is crucial for rapid disease control and symptom management in multiple myeloma patients.
• The VAD regimen, a combination of vincristine, doxorubicin, and dexamethasone, has been investigated for its efficacy.

Purpose:

• To evaluate the efficacy and safety of the VAD regimen as a primary treatment for multiple myeloma.
• To assess the response rates in both previously untreated and treated multiple myeloma patients.
• To determine the duration of response and the incidence of adverse events associated with the VAD regimen.

Summary:

• The VAD regimen was administered to 10 multiple myeloma patients (6 previously untreated, 4 treated).
• Response rates were 67% in previously untreated and 50% in previously treated patients, with significant M-protein decrease and clinical improvement in responders.
• Maintenance therapy with melphalan and prednisolone was given to responders. Infectious episodes occurred in 36.8% of patients, none serious. Response duration varied from 4 to 38 months.

Impact:

• The VAD regimen demonstrates utility as a primary treatment for multiple myeloma, particularly when rapid disease control is essential.
• The observed response rates and manageable safety profile support the consideration of VAD in specific multiple myeloma treatment scenarios.
• Further research may explore optimizing VAD combinations or sequencing for improved long-term outcomes in multiple myeloma.